Answers are grounded in this paper and cite their sources.
3H-cystine and 115mCd were incorporated into hepatic and renal cadmium-thionein in response to a subcutaneous administration of 4.4 micronmol of Cd2+ containing 115mCd. Cadmium-thionein bound 115mCd reached a plateau by 24 hrs. and 72 hrs. after the Cd2+ injection in liver and kidney, respectively. The half-life (t 1/2) of 3-H-labeled hepatic cadmium-thionein was 3.5 days, whereas the average t 1/2 of the soluble proteins was 3.7 days. The t 1/2 of the soluble renal proteins was 3.8 days. In marked contrast, the 115mCd content of both hepatic and renal cadmium-thionein was virtually unchanged even 9 days after administration of this radionuclide. These data indicate that the protein moiety of metallothionein is degraded, although there appears to be a concomitant rebinding of Cd2+ to nascent thionein polypeptide chains. Thus the lack of metallothionein degradation, per se, does not account for the long-term retention of Cd2+ in liver and kidney during chronic exposure.
No takes yet. Share an insight, caveat, or question.
Feldman et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: